Kura Oncology Q3 EPS Increased by Brookline Capital Markets

Key Points

• Brookline Capital Markets raised its Q3 2026 EPS estimate for Kura Oncology to a loss of $0.99 per share from a prior forecast of $1.06, while projecting a $3.48 per-share loss for fiscal 2026.
• Kura’s latest quarterly results beat expectations, with a loss of $0.77 per share versus the $0.88 consensus estimate and revenue of $20.87 million compared with expectations of $20.16 million.
• Analyst sentiment remains generally positive: 10 analysts rate the stock Buy, with an average price target of $25.62 versus its recent price of $10.86, although the company remains unprofitable and carries significant execution risk.

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Investment analysts at Brookline Capital Markets boosted their Q3 2026 earnings per share (EPS) estimates for Kura Oncology in a research report issued to clients and investors on Wednesday, August 12th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings per share of ($0.99) for the quarter, up from their prior estimate of ($1.06). The consensus estimate for Kura Oncology's current full-year earnings is ($3.30) per share. Brookline Capital Markets also issued estimates for Kura Oncology's Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($3.48) EPS, FY2027 earnings at ($2.53) EPS, FY2028 earnings at ($2.36) EPS and FY2030 earnings at $17.13 EPS.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.88) by $0.11. The firm had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.

Other analysts also recently issued research reports about the stock. Citizens Jmp reissued a "market outperform" rating and set a $24.00 target price on shares of Kura Oncology in a research report on Monday, June 15th. Jefferies Financial Group set a $24.00 price objective on shares of Kura Oncology in a research note on Thursday, May 28th. Wells Fargo & Company set a $24.00 price objective on shares of Kura Oncology in a research report on Thursday, June 4th. Citigroup reissued a "market outperform" rating on shares of Kura Oncology in a research note on Thursday, May 28th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Kura Oncology in a report on Thursday, June 4th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $25.62.

Kura Oncology Stock Performance

NASDAQ KURA opened at $10.86 on Monday. The firm has a market capitalization of $964.04 million, a P/E ratio of -3.22 and a beta of 0.38. Kura Oncology has a 1-year low of $6.95 and a 1-year high of $12.49. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71. The business's 50-day simple moving average is $10.22 and its 200-day simple moving average is $9.34.

Insider Transactions at Kura Oncology

In other news, insider Mollie Leoni sold 84,929 shares of Kura Oncology stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total transaction of $834,002.78. Following the sale, the insider owned 182,345 shares in the company, valued at $1,790,627.90. This trade represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KURA. IFP Advisors Inc grew its holdings in Kura Oncology by 115.3% during the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company's stock valued at $25,000 after purchasing an additional 1,284 shares in the last quarter. Allworth Financial LP lifted its holdings in Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company's stock worth $43,000 after buying an additional 1,553 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Kura Oncology by 49.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company's stock worth $60,000 after buying an additional 1,888 shares in the last quarter. Insigneo Advisory Services LLC purchased a new position in Kura Oncology in the 4th quarter valued at about $105,000. Finally, LPL Financial LLC purchased a new position in Kura Oncology in the 4th quarter valued at about $105,000.

Key Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: Quarterly results exceeded expectations: Kura reported a second-quarter loss of $0.77 per share, narrower than the roughly $0.88–$0.89 consensus loss, while revenue of $20.87 million topped estimates of approximately $20.16 million. The earnings beat may have improved sentiment toward the company’s execution. Kura Oncology Q2 earnings report
• Positive Sentiment: Analyst target increased substantially: Wedbush raised its price target from $36 to $38 and maintained an “outperform” rating. The target implies significant potential upside from the recent trading level, supporting bullish investor expectations. Wedbush raises Kura Oncology price target
• Positive Sentiment: Future revenue visibility: Management outlined a potential $90 million–$110 million in collaboration revenue for 2027 and is targeting 2028 topline results from the KOMET-017 study. These milestones could provide catalysts if development and commercial plans remain on track. Kura collaboration revenue and KOMET-017 update
• Neutral Sentiment: Clinical evidence remains under evaluation: Recent coverage examines what Kura’s latest update means for the clinical evidence supporting its pipeline. The implications for valuation depend on the strength and durability of upcoming data. Kura clinical evidence update
• Negative Sentiment: Analyst estimates are not uniformly improving: Brookline Capital Markets reduced its FY2029 EPS forecast to $5.70 from $6.01, while broader coverage describes conflicting analyst sentiment. Kura remains unprofitable, with analysts expecting a full-year loss, which could limit gains if development spending rises or milestones are delayed. Conflicting analyst sentiment on Kura Oncology

About Kura Oncology

Kura Oncology, Inc NASDAQ: KURA is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source